Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Christine Malboeuf"'
Autor:
Christine Malboeuf, Alan Sandler, Todd Riehl, Doron Lipson, Marcin Kowanetz, David R. Gandara, David Fabrizio, Yan Li, Marcus Ballinger, Priti S. Hegde, Wei Zou, Lukas C. Amler, David S. Shames, Jacob Silterra, Louis Fehrenbacher, Craig Cummings, Achim Rittmeyer, Erica B. Schleifman, Geoff Otto, Sarah M. Paul, Tony Mok, Daniel S. Lieber
Publikováno v:
Nature Medicine. 24:1441-1448
Although programmed death-ligand 1–programmed death 1 (PD-L1–PD-1) inhibitors are broadly efficacious, improved outcomes have been observed in patients with high PD-L1 expression or high tumor mutational burden (TMB). PD-L1 testing is required fo
Autor:
Jonathan K. Killian, Dean Pavlick, Lindsay Croshier, John Truesdell, Chris Wright, Tim Brennan, Vera Banning, Lazaro Garcia, Laurie Gay, Gene Stirchak, Jo-Anne Vergilio, Christine Malboeuf, Nhu Ngo, Julia Elvin, Siraj Ali, Vince Miller, Jeffrey S. Ross
Publikováno v:
Cancer Research. 79:1694-1694
Background. FNAC are generated during the FNA procedure - for example, commonly used in conjunction with endobronchial ultrasound (EBUS-FNA) as a minimally invasive tool for the diagnosis and management of non small-cell lung cancer (NSCLC) - as a hi
Autor:
David R. Gandara, Michael Coyne, Achim Rittmeyer, Louis Fehrenbacher, Marcus Ballinger, David S. Shames, Shan Zhong, Mark Kennedy, Erica B. Schleifman, Wei Zou, Tina Brennan, Craig Cummings, David Fabrizio, Priti S. Hegde, Doron Lipson, Marcin Kowanetz, Lukas C. Amler, Sarah M. Paul, Jacob Silterra, Alan Sandler, Yan Li, Emily White, Christine Malboeuf, Todd Riehl, Tony Mok, Daniel S. Lieber
Publikováno v:
Cancer Immunology Research. 6:A41-A41
Background: The need to identify biomarkers that predict benefit to checkpoint inhibitor therapies has led to the discovery and development of tumor mutational burden (TMB), a measure of potential tumor neoantigenicity derived from tissue biopsies th
Autor:
Sarah M. Paul, Michael Coyne, Jie Ma, Erica B. Schleifman, Marcin Kowanetz, Emily White, Jacob Silterra, Christine Malboeuf, Tina Brennan, David Fabrizio, David S. Shames, Mark Kennedy, Geoff Otto, Yan Li, Daniel S. Lieber, Eric Peters, Doron Lipson, Craig Cummings
Publikováno v:
Cancer Research. 78:5706-5706
Background: Tumor mutational burden (TMB) has emerged as a new biomarker for response to checkpoint inhibitor immunotherapy. Recently, we described a novel assay to calculate TMB from the circulating tumor DNA (ctDNA) in the blood (bTMB) and demonstr
Autor:
Christine Malboeuf, David S. Shames, Wei Zou, Todd Riehl, David Fabrizio, Alan Sandler, Craig Cummings, Achim Rittmeyer, Lukas C. Amler, G. Otto, Priti S. Hegde, Louis Fehrenbacher, Tony Mok, Erica B. Schleifman, Daniel S. Lieber, Marcin Kowanetz, David R. Gandara, Marcus Ballinger, Sarah M. Paul
Publikováno v:
ResearcherID
Publons
Publons
Autor:
Christine M. Lovly, Douglas B. Johnson, Geoff Otto, Shan Zhong, Catherine B. Meador, Doron Lipson, Vincent A. Miller, Kelsie Riemenschneider, Jie He, Kristina W. Brennan, Jeffrey S. Ross, Emily White, Philip J. Stephens, Christine Malboeuf
Publikováno v:
Cancer Research. 77:2367-2367
Background: Genomic alterations in the ALK tyrosine kinase, such as copy number gains, point mutations, and ALK gene fusions, have been described in a broad spectrum of malignancies. Recently a novel mechanism of ALK activation in melanoma was discov
Autor:
David S. Shames, Sarah M. Paul, David Fabrizio, Mike Coyne, Shan Zhong, Eric Peters, Jie He, Mark Kennedy, Doron Lipson, Tina Brennan, Yan Li, Jacob Silterra, G. Otto, Daniel S. Lieber, Craig Cummings, Emily White, J. Ma, Christine Malboeuf, Marcin Kowanetz, Erica B. Schleifman
Publikováno v:
Annals of Oncology. 28:v27
Autor:
Phil Stephens, Jeffrey S. Ross, Roman Yelensky, Siraj M. Ali, Emily White, Michael J. Hall, Christine Malboeuf, Vincent A. Miller, Mary B. Daly, John M. Kaczmar, Julia A. Elvin, Kyle Gowen, Eric M. Sanford, James Sun
Publikováno v:
Journal of Clinical Oncology. 34:1523-1523
1523Background: MSI status is predictive of anti-PD-1/L1 therapy efficacy independent of tumor histology. This study describes the development and validation of a novel computational method to assess MSI status. In addition, we sought to determine th
Autor:
Twist Bioscience Corporation
Publikováno v:
Business Wire (English). 02/14/2018.
Autor:
Brenda Macdougall
In recent years there has been growing interest in identifying the social and cultural attributes that define the Metis as both Aboriginal and a distinct people. The study of Metis identity formation has also emerged as an innovative way to explore c